Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q2 2026
Ironwood Pharmaceuticals (IRWD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Ironwood Pharmaceuticals (IRWD) reported revenue of $113M for the second quarter 2026 (Q2 2026), +33% from a year earlier and +6% from the quarter before. Operating margin was 70.2%, net earnings $51.3M (45.4% of revenue).
Ironwood Pharmaceuticals, Q2 2026: revenue $113M (+33% year over year), operating margin 70.2%, net earnings $51.3M, operating cash flow $58.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $113M | +6% | +33% |
| Operating profit | $79.3M | +9% | +75% |
| Net earnings | $51.3M | +26% | +117% |
| Operating cash flow | $58.3M | 11× | — |
What changed
Revenue was $113.0M in Q2 2026, up 33% year over year and up 6% from the previous quarter.
Operating profit was $79.3M, a 70.2% margin (up 17.0 points year over year). Of the extra revenue versus Q2 2025, 122% reached operating profit, above the 53% margin then. Total costs fell 15% while revenue rose 33%. Net earnings were $51.3M, up 117% year over year. The effective tax rate was 30.4%.
Operating cash flow was $58.3M, 114% of net earnings. Non-cash charges added back $457K of depreciation and $3.2M of share-based compensation. Working capital and other items added $3.3M.
Questions
What was Ironwood Pharmaceuticals' revenue in the second quarter 2026?
Ironwood Pharmaceuticals (IRWD) reported revenue of $113M for the second quarter 2026 (Q2 2026), +33% from a year earlier and +6% from the quarter before.
Was Ironwood Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $79.3M (70.2% of revenue) and net earnings $51.3M.